BioLineRX
BLRX
26 hedge funds and large institutions have $1.99M invested in BioLineRX in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 6 closing their positions.
28% more call options, than puts
Call options by funds: $37K | Put options by funds: $29K
0% less ownership
Funds ownership: 0.01% → 0% (-0%)
13% less funds holding
Funds holding: 30 → 26 (-4)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
61% less capital invested
Capital invested by funds: $5.09M → $1.99M (-$3.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWM
Apollon Wealth Management
Mount Pleasant,
South Carolina
|
+$98.2K |
| 2 |
Renaissance Technologies
New York
|
+$92.7K |
| 3 |
Morgan Stanley
New York
|
+$19.8K |
| 4 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
+$6.96K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$5.78K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$2.16M |
| 2 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$275K |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
-$92.4K |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
-$69K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$61.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIM
26
ARK Investment Management
St. Petersburg,
Florida
| – | -$2.16M | -26,493 | Closed |
|
|
JF
27
Jump Financial
Chicago,
Illinois
| – | -$69K | -848 | Closed |
|
|
GPFA
28
Game Plan Financial Advisors
Westlake,
Ohio
| – | -$37K | -450 | Closed |
|
29
Marshall Wace
London,
United Kingdom
| – | -$29K | -363 | Closed |
|
|
EGM
30
Engineers Gate Manager
New York
| – | -$22K | -269 | Closed |
|
|
AAS
31
Ameritas Advisory Services
Lincoln,
Nebraska
| – | -$21K | -261 | Closed |
|
32
Wells Fargo
San Francisco,
California
| – | -$1.18K | -17 | -94% |
|
BLRX Hedge Fund Activity: Q1 2022 in Review
26 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2022, worth a combined $1.99M — down 61% from $5.09M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BLRX and 4 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 6 added.
The largest buyer was Apollon Wealth Management, opening a new position worth an estimated $98.2K. The largest seller was ARK Investment Management, exiting entirely with an estimated $2.16M sold.
- 26 institutional investors held BioLineRX (BLRX) as of Q1 2022, down from 30 in Q4 2021.
- Funds reported $1.99M of BioLineRX stock for Q1 2022, down 61% quarter-over-quarter.
- 4 funds opened new BioLineRX positions in Q1 2022 and 6 closed out, a net change of -2 holders.
- The largest BioLineRX buyer in Q1 2022 was Apollon Wealth Management, an estimated $98.2K added.
- The largest BioLineRX seller in Q1 2022 was ARK Investment Management, an estimated $2.16M sold.
Based on aggregated 13F filings for Q1 2022.